GRCL - Gracell Biotechnologies - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart

Gracell Biotechnologies's activity chart (see below) currently has 24 price targets and 24 ratings on display.

Stock Analyst Price Targets - Review

Analysts' price targets on this stock were met 33.33% of the time, taking 76.33 days on average.

Most recent stock forecast was given by JOSEPH CATANZARO from MIZUHO on 27-Dec-2023. First documented stock forecast 30-Apr-2021.

Best performing analysts who are covering GRCL - Gracell Biotechnologies:

Joseph Catanzaro Yanan Zhu Emily Bodnar Yigal Nochomovitz Justin Zelin Benjamin Burnett

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 30-Apr-2021

$10

$10

2 years 10 months 26 days ago
(27-Dec-2023)

3/6 (50%)

$0.08 (0.81%)

261

Buy Since 27-Mar-2023

$10

$7

2 years 10 months 26 days ago
(27-Dec-2023)

3/3 (100%)

$0.08 (0.81%)

102

Buy Since 08-Dec-2022

$10

$13

2 years 10 months 27 days ago
(26-Dec-2023)

2/4 (50%)

$0.08 (0.81%)

95

Buy Since 04-Apr-2022

$20

2 years 10 months 27 days ago
(26-Dec-2023)

0/2 (0%)

$13.93 (229.49%)

Buy Since 19-Oct-2023

$11

3 years 1 months 3 days ago
(19-Oct-2023)

0/2 (0%)

$8.4 (323.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GRCL (Gracell Biotechnologies) average time for price targets to be met?

On average it took 76 days for the stock forecasts to be reached, with an average price target met ratio of 33.33%.

Which analyst most recently updated their price target on GRCL (Gracell Biotechnologies)?

Joseph Catanzaro

Which analyst has the lowest performance score on GRCL (Gracell Biotechnologies) with a proven track record?

BENJAMIN BURNETT

Which analyst has the most public recommendations on GRCL (Gracell Biotechnologies)?

Joseph Catanzaro works at MIZUHO and has 3 price targets and 2 ratings on GRCL

Which analyst is the currently most bullish on GRCL (Gracell Biotechnologies)?

Yigal Nochomovitz with the highest potential upside of $0.75

Which analyst is the currently most reserved on GRCL (Gracell Biotechnologies)?

Joseph Catanzaro with the lowest potential downside of -$0.25
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?